Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1 (Page 2)
113 posts, 0 comments

5/17/22 – RespireRx Pharmaceuticals Inc. Announces RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics

May 17, 2022j3ff1
Read More

5/16/22 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

May 16, 2022j3ff1
Read More

3/29/22 – WATCH: RespireRx Interim CEO Discusses Provisional Application for a Novel Lipid-Based Formulation Technology (LFT)

March 29, 2022j3ff1
Read More

3/24/2022 – Media Coverage: RespireRx Pharmaceuticals files provisional patent that may improve solubility of poorly soluble drugs

March 24, 2022j3ff1
Read More

3/23/2022 – RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol

March 23, 2022j3ff1
Read More

3/17/22 – Media Coverage: RespireRx Pharmaceuticals newest GABAkine

March 17, 2022j3ff1
Read More

3/16/22 – RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality

March 16, 2022j3ff1
Read More

3/10/22 – Proactive Investors: RespireRx Pharmaceuticals is developing innovative and revolutionary treatments to combat neuronal signaling disorders

March 10, 2022j3ff1
Read More

3/7/22 – Proactive Investors: RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022

March 10, 2022j3ff1
Read More

3/7/2022 – Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward

March 7, 2022j3ff1
Read More

Posts navigation

< 1 2 3 4 5 … 12 >

RespireRx Organization Structure

  • RespireRx Organization Structure
  • Arnold S. Lippa, PhD
    • Richard Purcell
    • David Dickason
    • James Cook
    • Jeffrey M. Witkin
    • Rok Cerne
  • Jeff Margolis
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.